Literature DB >> 16626757

Interferons and cognition.

X Montalban1, J Rio.   

Abstract

Cognitive impairment in multiple sclerosis is frequent, but the effect of immunomodulating drugs and mainly interferon beta (IFNbeta) on the neuropsychological aspects of the disease has not been fully studied. The data that we have are not conclusive. This paper reviews the effect of IFNbeta on cognition in the different clinical forms of the disease and the future directions of clinical trials.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16626757     DOI： 10.1016/j.jns.2005.08.022

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN： 0022-510X            Impact factor:   3.181


  7 in total

1.  Subcutaneous Interferon Beta-1a Has a Positive Effect on Cognitive Performance in Mildly Disabled Patients with Relapsing-Remitting Multiple Sclerosis: 2-Year Results from the COGIMUS Study.

Authors:  Francesco Patti; Maria Pia Amato; Stefano Bastianello; Luisa Caniatti; Elisabetta Di Monte; Fausto Lijoi; Benedetta Goretti; Silvia Messina; Orietta Picconi; Maria Rosalia Tola; Maria Trojano
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

2.  Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years.

Authors:  Sarah D Broicher; Linard Filli; Olivia Geisseler; Nicole Germann; Björn Zörner; P Brugger; M Linnebank
Journal:  J Neurol       Date:  2018-02-20       Impact factor: 4.849

3.  Plasma cytokine concentrations associated with HIV/hepatitis C coinfection are related to attention, executive and psychomotor functioning.

Authors:  Ronald A Cohen; Suzanne de la Monte; Assawin Gongvatana; Hernando Ombao; Beverly Gonzalez; Kathryn N Devlin; Bradford Navia; Karen T Tashima
Journal:  J Neuroimmunol       Date:  2010-12-10       Impact factor: 3.478

Review 4.  Cognitive impairment in multiple sclerosis.

Authors:  Alexander Winkelmann; Claudia Engel; Annett Apel; Uwe K Zettl
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

5.  Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C.

Authors:  Robert J Fontana; Linas A Bieliauskas; Carla Back-Madruga; Karen L Lindsay; Heather J Litman; Anna Sf Lok; Ziad Kronfol
Journal:  Am J Gastroenterol       Date:  2010-01-26       Impact factor: 10.864

6.  When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults?

Authors:  Mona Alkhawajah; Joel Oger
Journal:  Mult Scler Int       Date:  2011-05-17

7.  Cognitive dysfunction in multiple sclerosis.

Authors:  Joana Guimarães; Maria José Sá
Journal:  Front Neurol       Date:  2012-05-24       Impact factor: 4.003
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.